David M. Faleck

Memorial Sloan Kettering Cancer Center — United States

Medicine · Health Sciences

26h-index2.3kcitations152works1.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Microscopic Colitis(70), Inflammatory Bowel Disease(57), Cancer Immunotherapy and Biomarkers(40), Colorectal Cancer Treatments and Studies(32), Clostridium difficile and Clostridium perfringens research(24)

Publications152 total

Validation of the immune-mediated colitis endoscopic score using a retrospective cohort of patients with immune-mediated colitis
iGIE·2025· 1 citedOpen Access
Tu1781: MANAGEMENT OF GASTROINTESTINAL TOXICITY IN PATIENTS ON IMMUNE CHECKPOINT INHIBITORS WITH PREEXISTING INFLAMMATORY BOWEL DISEASE
Gastroenterology·2025
Tu1790: PRESENTATION AND MANAGEMENT OF IMMUNE CHECKPOINT INHIBITOR-RELATED ESOPHAGITIS
Gastroenterology·2025
1010: INFLAMMATORY BOWEL DISEASE-DIRECTED THERAPY REDUCES RISK OF SEVERE INTESTINAL TOXICITY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE STARTING IMMUNE CHECKPOINT INHIBITORS
Gastroenterology·2025
Tu1782: UPADACITINIB FOR TREATMENT OF IMMUNE CHECKPOINT INHIBITOR-RELATED COLITIS: A CASE-SERIES
Gastroenterology·2025
Management and Outcomes of Clostridioides difficile Infection in Patients on Immune Checkpoint Inhibitors
Journal of the National Comprehensive Cancer Network·2025· 1 citedOpen Access
608 Diffuse Lymphocytic-Predominant Esophagitis with Dyskeratosis Is Helpful for a Diagnosis of Immunotherapy-Associated Esophagitis
Laboratory Investigation·2025Open Access
Immune Checkpoint Inhibitor Use in Patients with Pre-Existing Inflammatory Bowel Disease
2025
Baseline colitogenicity and acute perturbations of gut microbiota in immunotherapy-related colitis
The Journal of Experimental Medicine·2024· 5 citedOpen Access
Immune Checkpoint Inhibitor–Induced Colitis
Gastroenterology·2024· 2 citedOpen Access
Open-capsule budesonide for the treatment of immune-related enteritis from checkpoint inhibitors
Journal for ImmunoTherapy of Cancer·2024· 8 citedOpen Access
Safety of Immunosuppression in a Prospective Cohort of Inflammatory Bowel Disease Patients With a HIstoRy of CancEr: SAPPHIRE Registry
Clinical Gastroenterology and Hepatology·2024· 13 citedOpen Access
Sa1915 OUTCOMES AND MANAGEMENT OF CLOSTRIODIODIES DIFFICILE INFECTION IN PATIENTS ON IMMUNE CHECKPOINT INHIBITORS
Gastroenterology·2024
Tu1914 OFFICE-BASED FLEXIBLE SIGMOIDOSCOPY ALLOWS RAPID ASSESSMENT AND MANAGEMENT OF SUSPECTED IMMUNE CHECKPOINT INHIBITOR-RELATED COLITIS
Gastroenterology·2024
Tu1910 OPEN-CAPSULE BUDESONIDE FOR THE TREATMENT OF IMMUNE-RELATED ENTERITIS FROM CHECKPOINT INHIBITORS
Gastroenterology·2024
Tu1913 CHRONIC IMMUNE-RELATED COLITIS IS COMMON AFTER PD-(L)1 TREATMENT AND MAY BE MITIGATED THROUGH EARLY USE OF BIOLOGIC THERAPY
Gastroenterology·2024
Tu1912 ROLE OF FECAL CALPROTECTIN IN DISTINGUISHING DIARRHEA FROM IMMUNOTHERAPY-RELATED ENTEROCOLITIS VERSUS CHEMO OR TKI-RELATED DIARRHEA IN PATIENTS ON COMBINATION THERAPIES
Gastroenterology·2024
Sa1848 EXTENT OF SURGICAL RESECTION FOR IBD-ASSOCIATED NEOPLASIA AND COLORECTAL CANCER OUTCOMES
Gastroenterology·2024
Polygenic risk score for ulcerative colitis predicts immune checkpoint inhibitor-mediated colitis
Nature Communications·2024· 26 citedOpen Access
Abstract 924: Patterns of specialty referral in cancer patients treated with immunotherapy regimens
Cancer Research·2024
page 1 of 8Next →

Frequent Co-authors

Arun Swaminath(14), Eugenia Shmidt(13), Dana J. Lukin(13), Jean‐Frédéric Colombel(13), Joseph Meserve(12), Gursimran Kochhar(12), Jenna L. Koliani‐Pace(12), Robert Hirten(12), Brigid S. Boland(12), Siddharth Singh(12), Monika Fischer(12), Matthew Bohm(12), David Hudesman(12), Bo Shen(12), Sunanda V. Kane(12), Edward V. Loftus(12), Corey A. Siegel(12), William J. Sandborn(12), Parambir S. Dulai(12), Adam C. Winters(11)